Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: Clinical and biological activity

British Journal of Cancer

Volumn 99, Issue 10, 2008, Pages 1564-1571

  Torrisi, R ^a   Bagnardi, V ^a,b   Cardillo, A ^a   Bertolini, F ^a   Scarano, E ^a   Orlando, L ^a   Mancuso, P ^a   Luini, A ^a   Calleri, A ^a   Viale, G ^a,c   Goldhirsch, A ^a   Colleoni, M ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Bevacizumab; Chemoendocrine therapy; Endocrine responsive breast cancer; Preoperative therapy

Indexed keywords

BEVACIZUMAB; CAPECITABINE; ESTROGEN RECEPTOR; LETROZOLE; NAVELBINE; PROGESTERONE RECEPTOR; TRIPTORELIN;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BILIRUBIN BLOOD LEVEL; BREAST CANCER; CANCER STEM CELL; CLINICAL ARTICLE; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; ENDOTHELIUM CELL; EPIGASTRIC PAIN; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; INFECTION; LEUKOPENIA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROTEINURIA; SIDE EFFECT; STIPSIS; VOMITING;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NITRILES; PREOPERATIVE CARE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TRIAZOLES;

EID: 55949102088     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604741     Document Type: Article

References (42)

1. Banerjee S, Dowsettt M, Ashworth A, Martin L-A (2007) Mechanisms of disease: angiogenesis and the management of breast cancer. Nat Clin Pract 4: 536-550
2. Banerjee S, Pancholi S, A'Hern R, Ghazoui Z, Smith IE, Dowsett M, Martin L-A (2008) The effects of neoadjuvant anastrozole and tamoxifene on circulating vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 in breast cancer. Clin Cancer Res 14: 2656-2663
3. Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y, Kerbel RS (2003) Maximum tolerable dose and low-dose metronomic therapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 53: 4342-4346
4. Bertolini F, Shaked Y, Mancuso P, Kerbel RS (2006) The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer 6: 835-845
5. Bottini A, Berruti A, Brizzi MP, Bersiga A, Generali D, Allevi G, Aguggini S, Bolsi G, Bonardi S, Tondelli B, Vana F, Tampellini M, Alquanti P, Dogliotti L (2005) Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trial. Endocr Relat Cancer 12: 383-392
6. Burcombe RJ, Makris A, Richman PI, Daley FM, Noble S, Pittam M, Wright D, Allen SA, Dove J, Wilson GD (2005) Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br J Cancer 92: 147-155
7. Burstein HJ, Parker LM, Savoie J, Younger J, Kuter I, Ryan PD, Garber JE, Campos SM, Shulman LN, Harris LN, Gelman R, Winer EP (2002) Phase II trial of the anti-VEGF antibody bevacizumab in combination with vinorelbine for refractory advanced breast cancer. Breast Cancer Res Treat 76(Suppl 1): S115
8. Chang J, Powles TJ, Allred DC, Ashley SE, Clark GM, Makris A, Assersohn L, Gregory RK, Osborne CK, Dowsett M (1999) Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol 17: 3058-3063
9. Cobleigh MA, Langmuir VK, Sledge GW, Miller KD, Haney L, Novotny WF, Reimann JD, Vassel A (2003) A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 30(Suppl 16): 117-124
10. Colleoni M, Viale G, Zahrieh D, Bottiglieri L, Gelber RD, Veronesi P, Balduzzi A, Torrisi R, Luini A, Intra M, Dellapasqua S, Cardillo A, Ghisini R, Peruzzotti G, Goldhirsch A (2008) Expression of ER, PgR, HER1, HER2 and response : a study of preoperative chemotherapy. Ann Oncol 19: 465-472
11. Colleoni M, Viale G, Zahrieh D, Pruneri G, Gentilini O, Veronesi P, Gelber RD, Curigliano G, Torrisi R, Luini A, Intra M, Galimberti V, Renne G, Nolè F, Peruzzotti G, Goldhirsch A (2004) Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res 10: 6626-6628
12. Dowsett M, Ebbs SR, Dixon M, Skene A, Griffith C, Boeddinghaus I, Walter J, Detre S, Hills M, Ashley S, Francis S, Walsh G, Smith IE (2005) Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER2 in breast cancer - a study from the IMPACT trialists. J Clin Oncol 23: 2477-2492
13. Foekens JA, Peters HA, Grebenchtchickov N, Look MP, Mejier-van Gelder ME, Geurts-Moespot A, van der Kwast TH, Sweep CG, Klijn JG (2001) High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res 61: 5407-5414
14. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186
15. Forero-Torres A, Percent J, Galleshaw L, Nabell J, Carpenter C, Falkson C, Jones H, Krontriras J, De Los Santos M, Saleh UAB, Breast Cancer Working Group (2007) A study of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed operable breast cancer. A preliminary safety report. Proc Am Soc Clin Oncol 25(18S): 11020
16. Furstenberger G, von Moos R, Lucas R, Thurlimann B, Senn HJ, Hamacher J, Boneberg EM (2006) Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br J Cancer 94: 524-531
17. Greil R, Moik M, Reitsamer R, Ressler S, Stoll M, Namberger K, Menzel C, Mlineritsch B (2007) Capecitabine+docetaxel+bevacizumab as neoadjuvant therapy for invasive breast cancer: results of a phase II pilot study. Breast Cancer Res Treat 106: S188 (abstract 4064)
18. Guarneri V, Broglio K, Kau SW, Cristofanilli M, Buzdar AU, Valero V, Buchholz T, Meric F, Middleton L, Hortobagyi GN, Gonzalez-Angulo AM (2006) Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 24: 1037-1044
19. Jones RL, Salter A, Nerukar M, Parton M, A'Hern R, Smith IE, Dowsett M (2007) Prognostic significance of Ki67 before and after neoadjuvant chemotherapy in early breast cancer. Proc Am Soc Clin Oncol 25(18S): 573
20. Kaufmann M, Hortobagyi GN, Goldhirsch A, Scholl S, Makris A, Valagussa P, Blohmer JU, Eiermann W, Jackesz R, Jonat W, Lebeau A, Loibl S, Miller W, Seeber S, Semiglazov V, Smith R, Souchon R, Stearns V, Untch M, von Minckwitz G (2006) Recommendations from an International Export Panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 24: 1940-1949
21. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 362: 841-844
22. Kuerer HM, Newman LA, Smith TM, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Bucholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN, Singletary SE (1999) Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17: 460-469
23. Lyons JA, Silverman P, Remick S, Chen H, Leeming R, Shenk R, Fu P, Dumadag L, Escuro K, Overmoyer B (2006) Toxicity results and early outcome on a randomized phase II study of docetaxel ± bevacizumab for locally advanced, unresectable breast cancer. Proc Am Soc Clin Oncol 24(18S): 3049
24. Mancuso P, Colleoni M, Calleri A, Orlando L, Maisonneuve P, Pruneti G, Agliano A, Goldhirsch A, Shaked Y, Kerbel RS, Bertolinif F (2006) Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 108: 452-459
25. Manders P, Beex LV, Tjan-Helijnen VC, Span PN, Sweep CG (2003) Vascular endothelial growth factor is associated with the efficacy of endocrine therapy in patients with advanced breast carcinoma. Cancer 98: 2125-2132
26. Mazouni C, Kau SW, Frye D, Andre F, Kuere HM, Bucholz TA, Symmans WF, Anderson K, Hess KR, Gonzalez-Angulo AM, Hortobagyi GN, Buzdar AU, Pusztai L (2007) Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor positive breast cancers. Ann Oncol 18: 874-880
27. Miller K, Wang M, Gralow J, Dickler M, Cobleigh MA, Perez EA, Shenkier T, Cella D, Davidson NE (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357: 2666-2676
28. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23: 792-799
29. Nolè F, Catania C, Munzone E, Rocca A, Verri E, Sanna G, Ascione G, Adamoli L, Zampino MG, Minchella I, Goldhirsch A (2006) Capecitabine/ vinorelbine: an effective and well-tolerated regimen for women with pretreated advanced stage breast cancer. Clin Breast Cancer 6: 518-524
30. Philpott NJ, Turner AJ, Scopes J, Westby M, Marsh JC, Gordon-Smith EC, Dalgleish AG, Gibson FM (1996) The use of 7-amino actinomycin D in identifying apoptosis: simplicity of use and broad spectrum of application compared with other techniques. Blood 87: 2244-2251
31. Relf M, LeJeune S, Scott PA, Fox S, Smith K, Leek R, Moghaddam A, Whitehouse R, Bicknell R, Harris AL (1997) Expression of the angiogenic factprs vascular endothelial growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet derived endothelial growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and is relation to angiogenesis. Cancer Res 57: 963-969
32. Richter-Ehrenstein C, Rentzsch J, Runkel S, Schneider A, Schonfelder G (2007) Endothelial progenitor cells in breast cancer patients. Breast Cancer Res Treat 106: 343-349
33. Ring AE, Smith IE, Ashley S, Fulford LG, Lakhani SR (2004) Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer 91: 2012-2017
34. Shaked Y, Bertolini F, Man S, Rogers MS, Cervi D, Foutz T, Rawn K, Voskas D, Dumont DJ, Ben-David Y, Lawler J, Henkin J, Huber J, Hicklin DJ, D'Amato RJ, Kerbel RS (2005) Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis: implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 7: 101-111
35. Shaked Y, Ciarrocchi A, Franco M, Lee CR, Man S, Cheung AS, Hicklin DJ, Chaplin D, Foster FS, Benezra R, Kerbel RS (2006) Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumours. Science 313: 1785-1787
36. Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK, Shen J, Sledge Jr GW (2001) The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxiestradiol but antagonized by endothelial growth factors. Cancer Res 61: 3369-3672
37. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweji L, Van Glabbeke M, van Osteroom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumours. J Natl Cancer Inst 92: 205-216
38. Torrisi R, Dellapasqua S, Ghisini R, Viale G, Veronesi P, Luini A, Intra M, Peruzzotti G, Rocca A, Balduzzi A, Cardillo A, Goldhirsch A, Colleoni M (2008) Preoperative concurrent chemo- and endocrine therapies for women with large operable breast cancer expressing steroid hormone receptors. The Breast; (e-pub ahead of print)
39. Traina TA, Rugo HS, Dickler M (2007) Bevacizumab for advanced breast cancer. Hematol Oncol Clin North Am 21: 303-319
40. von Minckwitz G, Costa SD, Raab G, Blohmer JU, Eidtmann H, Hilfrich J, Merkle E, Jackisch C, Gademann G, Tulusan AH, Eiermann W, Graf G, Kaufmann M (2001) Dose-dense doxorubicin, docetaxel and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled open phase IIb study. J Clin Oncol 19: 3506-3515
41. Wedam SB, Low JA, Yang SX, Chow CK, Choyke P, Danforth DH, Hewitt SM, Berman A, Steinberg SM, Liewehr DJ, Plehn J, Doshi A, Thomasson D, McCarthy N, Koeppen H, Sherman M, Zujewski J, Camphausen K, Chen H, Swain SM (2006) Antiangiogenic and antitumour effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 24: 769-777
42. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Xhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GJ, Jain RK (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10: 145-147